Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07167862 · ClinicalTrials.gov registry record · Phase 4
Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound
A Phase 4 study, sponsored by University of California, Irvine.
- Not yet
- Registry status
- Phase 4
- Development phase
- 96
- Enrollment target
NCT07167862 is a Phase 4 study that has not yet begun recruiting, run by University of California, Irvine. The registered enrollment target is 96 participants.
The verdict
NCT07167862, a Phase 4 study, has not yet begun recruiting, sponsored by University of California, Irvine.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 96 participants
- Enrollment target
Study Summary
This study explores a novel approach to improving care for postpartum patients with preeclampsia, a pregnancy-related condition characterized by high blood pressure, protein in the urine, and organ dysfunction. Preeclampsia affects up to 9% of pregnancies and can progress to include complications of seizures, stroke, and even death. Over 60% of patients with preeclampsia continue to experience high blood pressure at the time of discharge from their delivery hospitalization, and many of these patients require blood pressure medications for up to 6 months postpartum. Even with blood pressure medications, many of these patients are readmitted to the hospital within six weeks of delivery. In this study, the investigators will utilize point-of-care ultrasound (POCUS), a quick and non-invasive, bedside imaging strategy, to look for signs of excess fluid accumulating in the lungs and venous system of postpartum patients with preeclampsia. Because excess fluid has the potential to worsen blood pressure, subjects with evidence of this on POCUS would be treated with a diuretic medication called furosemide (either orally or intravenously) within 24 hours of delivery. The investigators' main goal is to determine whether using POCUS can help physicians make better treatment decisions and improve short-term outcomes for postpartum patients with preeclampsia. The investigators' aim to achieve faster recovery of blood pressure, reduce the need for blood pressure medication at hospital discharge, and lower the rates of hospital readmission for those with preeclampsia. This study could significantly enhance the overall care and health of postpartum patients.
Interventions
- DRUG Oral furosemide
- DIAGNOSTIC_TEST Butterfly iQ3 ultrasound system for determination of postpartum volume status
- DRUG Intravenous furosemide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2026-06-15 |
| Est. Completion | 2028-06-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07167862
The ClinicalTrials.gov registry entry for NCT07167862 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Oral furosemide is the first listed.
NCT07167862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07167862 about?
NCT07167862 is a clinical study titled "Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound". This study explores a novel approach to improving care for postpartum patients with preeclampsia, a pregnancy-related condition characterized by high blood pressure, protein in the urine, and organ dysfunction. Preeclampsia affects up to 9% of pregnancies and can progress to include complications of...
What is the current status of trial NCT07167862?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 96 participants. The study started on 2026-06-15. Estimated completion is 2028-06-15.
What interventions are being tested in trial NCT07167862?
The interventions under investigation include: Oral furosemide (DRUG), Butterfly iQ3 ultrasound system for determination of postpartum volume status (DIAGNOSTIC_TEST), Intravenous furosemide (DRUG).
Who is sponsoring clinical trial NCT07167862?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.